remdesivir in COVID-19 - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results CAP-China (Wang et al.), 2020 1.10 [0.49; 2.45]
GS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50]
GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86]
NIH NIAID ACTT-1, 2020 0.70 [0.47; 1.04]
SOLIDARITY (remdesivir), 2020 0.95 [0.81; 1.11]
0.91 [0.79 ; 1.05 ] CAP-China (Wang et al.), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NIH NIAID ACTT-1, 2020, SOLIDARITY (remdesivir), 2020 5 0% 8,917 moderate not evaluable deaths (time to event analysis only)detailed results NIH NIAID ACTT-1, 2020 0.70 [0.47; 1.04]
SOLIDARITY (remdesivir), 2020 0.95 [0.81; 1.11]
0.86 [0.65 ; 1.14 ] NIH NIAID ACTT-1, 2020, SOLIDARITY (remdesivir), 2020 2 49% 7,897 moderate not evaluable clinical improvementdetailed results CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
GS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74]
GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49]
NIH NIAID ACTT-1, 2020 1.32 [1.12; 1.55]
1.32 [1.16 ; 1.50 ] CAP-China (Wang et al.), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NIH NIAID ACTT-1, 2020 4 0% 2,092 moderate not evaluable clinical improvement (14-day)detailed results CAP-China (Wang et al.), 2020 1.21 [0.64; 2.28]
GS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47]
GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44]
1.49 [1.13 ; 1.98 ] CAP-China (Wang et al.), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 0% 1,020 moderate not evaluable clinical improvement (28-day)detailed results CAP-China (Wang et al.), 2020 1.37 [0.79; 2.39]
GS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42]
GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17]
1.64 [1.17 ; 2.29 ] CAP-China (Wang et al.), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 0% 1,020 moderate not evaluable clinical improvement (7-day)detailed results CAP-China (Wang et al.), 2020 0.99 [0.18; 5.51]
GS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53]
GS-US-540-5774, 5 days, 2020 1.53 [1.01; 2.34]
1.23 [0.93 ; 1.64 ] CAP-China (Wang et al.), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 0% 1,020 moderate not evaluable clinical improvement (time to event analysis only)detailed results CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
1.23 [0.87 ; 1.74 ] CAP-China (Wang et al.), 2020 1 0% 237 low not evaluable death or ventilationdetailed results SOLIDARITY (remdesivir), 2020 0.97 [0.85; 1.10]
0.97 [0.85 ; 1.10 ] SOLIDARITY (remdesivir), 2020 1 0% 5,451 moderate not evaluable ventilationdetailed results SOLIDARITY (remdesivir), 2020 1.04 [0.87; 1.23]
1.04 [0.87 ; 1.23 ] SOLIDARITY (remdesivir), 2020 1 0% 4,964 moderate not evaluable AE leading to drug discontinuationdetailed results CAP-China (Wang et al.), 2020 2.43 [0.79; 7.45]
2.43 [0.79 ; 7.45 ] CAP-China (Wang et al.), 2020 1 0% 233 low not evaluable serious adverse eventsdetailed results CAP-China (Wang et al.), 2020 0.64 [0.33; 1.23]
NIH NIAID ACTT-1, 2020 0.72 [0.54; 0.96]
0.71 [0.55 ; 0.92 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable deep vein thrombosisdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
NIH NIAID ACTT-1, 2020 0.64 [0.23; 1.81]
0.62 [0.23 ; 1.64 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable elevated liver enzymesdetailed results CAP-China (Wang et al.), 2020 0.36 [0.13; 1.01]
NIH NIAID ACTT-1, 2020 0.67 [0.38; 1.18]
0.58 [0.34 ; 0.97 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 6% 1,296 moderate not evaluable hyperbilirubinemiadetailed results CAP-China (Wang et al.), 2020 1.09 [0.42; 2.79]
NIH NIAID ACTT-1, 2020 0.84 [0.30; 2.34]
0.97 [0.48 ; 1.93 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable pulmonary embolismdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
NIH NIAID ACTT-1, 2020 0.96 [0.19; 4.80]
0.82 [0.20 ; 3.29 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable renal impairmentdetailed results CAP-China (Wang et al.), 2020 1.01 [0.03; 30.33]
NIH NIAID ACTT-1, 2020 1.02 [0.64; 1.61]
1.02 [0.64 ; 1.61 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2021-01-20 14:19 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 87,95,94,90,91,97
- treatments: 510
- roots T: 290
